Literature DB >> 27467126

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.

Yoon-Kyung Chang, Hyunsu Choi, Jin Young Jeong, Ki-Ryang Na, Kang Wook Lee, Beom Jin Lim, Dae Eun Choi.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0158810.].

Entities:  

Year:  2016        PMID： 27467126      PMCID： PMC4965079          DOI： 10.1371/journal.pone.0160478

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


The affiliation for the sixth author, Beom Jin Lim, is spelled incorrectly. The correct affiliation is: Department of Pathology, College of Medicine, Yonsei University, Seoul, South Korea.
  1 in total

1.  Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.

Authors:  Yoon-Kyung Chang; Hyunsu Choi; Jin Young Jeong; Ki-Ryang Na; Kang Wook Lee; Beom Jin Lim; Dae Eun Choi
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240
  1 in total
  4 in total

1.  Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha.

Authors:  Angelamellisy Revelian Ndibalema; Deo Kabuye; Si Wen; Lulu Li; Xin Li; Qiuling Fan
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-12       Impact factor: 3.168

2.  Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death.

Authors:  Ryo Shibusawa; Eijiro Yamada; Shuichi Okada; Yasuyo Nakajima; Claire C Bastie; Akito Maeshima; Kyoichi Kaira; Masanobu Yamada
Journal:  Sci Rep       Date:  2019-07-08       Impact factor: 4.379

3.  Dapagliflozin Alleviates Renal Fibrosis by Inhibiting RIP1-RIP3-MLKL-Mediated Necroinflammation in Unilateral Ureteral Obstruction.

Authors:  Mei Ying Xuan; Shang Guo Piao; Jun Ding; Qi Yan Nan; Mei Hua Piao; Yu Ji Jiang; Hai Lan Zheng; Ji Zhe Jin; Can Li
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

4.  Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.

Authors:  Arnaud D Kaze; Min Zhuo; Seoyoung C Kim; Elisabetta Patorno; Julie M Paik
Journal:  Cardiovasc Diabetol       Date:  2022-03-23       Impact factor: 8.949
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.